Ophthalmology · Ocoee, FL
NPI
1316240690
Since 2010
Specialty
Ophthalmology
Code 207W00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
10131 W Colonial Dr
Ocoee, FL, 34761
Phone (407) 206-2020
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
18,541 services
Medicare patients, 2024
1,017
Average age 78
Drug cost, 2024
$2.1M
3,841 prescriptions
Company payments, 2025
$2,100
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Samantha Xavier was code 92134 (computerized ophthalmic imaging), 1,910 times for 891 patients. In total Samantha Xavier billed 18,541 services in 37 codes, and Medicare paid $1.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-07-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 92134 Computerized Ophthalmic Imaging | Office | 1,910 | 891 | $28.52 | $54K |
| J0178 Injection, aflibercept, 1 mg | Office | 1,244 | 120 | $657.59 | $818K |
| 92014 Ophthalmological E&M | Office | 990 | 764 | $83.81 | $83K |
| 67028 Intravitreal Injection | Office | 927 | 165 | $85.58 | $79K |
| 92012 Ophthalmological E&M | Office | 269 | 179 | $61.08 | $16K |
| J3490 Unclassified drugs | Office | 150 | 53 | $62.13 | $9,319 |
| 92250 Angiography | Office | 81 | 61 | $28.15 | $2,280 |
| 99213 Office E&M - Established | Office | 74 | 62 | $58.51 | $4,330 |
| 92004 Ophthalmological E&M | Office | 34 | 34 | $98.75 | $3,357 |
| 99212 Office E&M - Established | Office | 25 | 22 | $44.13 | $1,103 |
| 76512 Ultrasound - Nonspecific | Office | 21 | 15 | $32.81 | $689 |
| 92083 Vision, Hearing, and Speech Services | Office | 15 | 15 | $50.02 | $750 |
By year: 2022 $1.1M for 6,149 services; 2023 $1.1M for 57,317 services; 2024 $1.3M for 18,541 services.
Medicare prescription drug claims, 2024
In 2024, the drug Samantha Xavier prescribed most often to Medicare patients was Ketorolac Tromethamine, with 620 prescriptions and refills. In total Samantha Xavier wrote 3,841 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketorolac Tromethamine Generic | 620 | 715 | 227 | $20K |
| Eylea Aflibercept | 570 | 731 | 122 | $1.4M |
| Prednisolone Acetate Generic | 514 | 703 | 230 | $17K |
| Latanoprost Generic | 415 | 916 | 159 | $3,579 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 392 | 940 | 150 | $5,360 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 170 | 172 | 124 | $2,261 |
| Timolol Maleate Generic | 161 | 341 | 64 | $2,659 |
| Cyclopentolate Hcl Generic | 129 | 153 | 102 | $1,448 |
| Brimonidine Tartrate Generic | 101 | 182 | 34 | $4,577 |
| Dorzolamide Hcl Generic | 88 | 195 | 38 | $1,283 |
| Erythromycin Erythromycin Base | 67 | 67 | 49 | $665 |
| Atropine Sulfate Generic | 61 | 106 | 35 | $1,582 |
| Restasis Cyclosporine | 54 | 113 | 23 | $69K |
| Syfovre Pegcetacoplan/Pf | 52 | 96 | 13 | $131K |
| Vabysmo Faricimab-Svoa | 42 | 54 | Under 11 | $113K |
Brand drugs: 1,716 claims; generic drugs: 2,125 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Samantha Xavier $2,100 ($2,100 in general payments such as food, travel and fees) from 14 companies. The largest payer was Bausch & Lomb Americas Inc. with $715.
| Company | Payments | Amount |
|---|---|---|
| Bausch & Lomb Americas Inc. BLCO | 7 | $715 |
| Glaukos Corporation GKOS | 2 | $342 |
| Alcon Vision LLC ALC | 4 | $234 |
| Harrow Eye, LLC | 7 | $218 |
| Tarsus Pharmaceuticals, Inc. TARS | 2 | $144 |
| Astellas Pharma US Inc 4503.T | 8 | $137 |
| Apellis Pharmaceuticals, Inc. APLS | 7 | $137 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $55.19 |
| Rayner Intraocular Lenses Limited | 1 | $41.92 |
| ANI Pharmaceuticals, Inc. ANIP | 2 | $39.86 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.